BC Extra | Aug 22, 2019
Company News

Aug. 21 Company Quick Takes: GSK, FibroGen take regulatory steps forward for HIF-PH inhibitors in Asia; plus Xtandi, Biotheus/Alligator and more

GSK seeking approval of HIF-PH inhibitor in Japan  GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said it submitted an NDA to Japan's Ministry of Health, Labour and Welfare for daprodustat to treat patients with renal anemia due to...
BC Extra | May 16, 2019
Clinical News

Roche, Bayer unveil brain tumor data for NTRK inhibitors ahead of ASCO

Efficacy data for two tissue-agnostic NTRK inhibitors from Roche and Bayer to treat primary and metastatic brain tumors were released in abstracts ahead of the American Society of Clinical Oncology meeting in Chicago. Data from...
BC Innovations | Oct 25, 2018
Targets & Mechanisms

Blueprint for selectivity

Blueprint Medicines Corp. is making the jump from cancer to rare disease with an inhibitor for the rare pediatric bone disease FOP that sets the company up against at least two competitors further ahead in...
BC Week In Review | Feb 2, 2018
Company News

Pfizer, Kintor in deal for ACVRL1 mab

Pfizer Inc. (NYSE:PFE) granted Suzhou Kintor Pharmaceuticals Inc. (Suzhou, China) exclusive, worldwide rights to develop and commercialize PF-03446962 (PF-3446962), a human mAb against activin receptor-like kinase 1 (ACVRL1; ALK1; HHT2). Pfizer may opt to obtain...
BC Week In Review | Jun 16, 2017
Clinical News

Acceleron discontinues dalantercept after Phase II miss

Acceleron Pharma Inc. (NASDAQ:XLRN) discontinued development of dalantercept (ACE-041) after reporting top-line data from 119 evaluable patients with advanced renal cell carcinoma (RCC) in the double-blind part 2 of the Phase II DART trial showing...
BC Extra | Jun 12, 2017
Clinical News

Acceleron's dalantercept fails in Phase II RCC trial

Acceleron Pharma Inc. (NASDAQ:XLRN) said it is discontinuing development of dalantercept ( ACE-041 ) after the candidate missed the primary endpoint in the Phase II DART study to treat advanced renal cell carcinoma. Among 119 evaluable patients,...
BC Week In Review | Mar 16, 2015
Clinical News

Dalantercept: Additional Phase II data

Data from 28 evaluable patients with metastatic RCC in the first part of the 2-part, U.S. Phase II DART trial showed that subcutaneous 0.6, 0.9 or 1.2 mg/kg dalantercept given once every 3 weeks plus...
BC Week In Review | Oct 6, 2014
Clinical News

Dalantercept: Interim Phase II data

Interim data from an open-label, U.S. Phase II trial evaluating Acceleron's dalantercept as monotherapy in patients with recurrent or persistent epithelial ovarian cancer showed that 6 of 30 patients were progression free without receiving non-protocol...
BC Week In Review | May 26, 2014
Clinical News

Dalantercept: Interim Phase II data

Interim data from 20 evaluable patients with metastatic RCC in the first part of a 2-part, U.S. Phase II trial showed that subcutaneous 0.6, 0.9 or 1.2 mg/kg dalantercept given once every 3 weeks plus...
BC Innovations | Apr 3, 2014
Targets & Mechanisms

Narrowing down graft stenosis

One of the dominant problems after coronary artery bypass graft surgery is hyperplastic growth inside the transplanted blood vessel that can lead to stenosis. Now, a team at the NIH 's National Heart, Lung, and...
Items per page:
1 - 10 of 19